排卵誘発剤の世界市場レポート 2024

排卵誘発剤の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.6%の年間複合成長率（CAGR）で57億米ドルに成長すると予想されます。予測期間中に予想される成長は、ライフスタイルの変化と出産の遅れ、デジタルヘルスの統合、市場範囲の拡大、不妊率の増加、カスタマイズされた治療計画の採用に起因すると考えられます。予測期間中に予想される主な動向には、個別化された治療アプローチ、生殖内分泌学の進歩、非侵襲的生殖能力モニタリング、生殖補助技術に対する需要の高まり、新規製剤の開発などが含まれます。

女性の不妊症の有病率の予想される増加により、排卵誘発剤市場の拡大が促進される見込みです。女性の不妊症は、定期的に無防備な性交を行っているにもかかわらず、妊娠できない、または満期まで妊娠できないことを特徴としており、15～44歳の女性のかなりの割合が罹患しています。排卵不順または排卵欠如の問題に対処するために設計された排卵誘発剤は、ホルモンを標的としています。排卵プロセスに関与する経路で、卵巣からの成熟卵子の放出を刺激します。たとえば、疾病管理予防センターのデータによると、米国の女性の約10%（合計 610万人）が妊娠困難に直面しています。さらに、CCRM Management Company LLCは、世界中で4組に1組のカップルが不妊症の影響を受けており、その割合は毎年 5%～10%増加していると報告しています。その結果、女性の不妊症の蔓延が排卵誘発剤市場の主要な促進要因となっています。

体外受精（IVF）を選択する患者の急増は、排卵誘発剤市場の成長を促進すると予想されます。 IVFは、妊孕性の課題を抱える個人やカップルを支援する一連の複雑な処置であり、排卵誘発剤を使用して卵巣を刺激し、回収のための卵子の生産を促進します。このアプローチは、体外受精の成功率を最適化するために不可欠です。特に、ヒト受精・発生学当局の報告書は、英国での体外受精およびドナー授精治療が増加し、2023年には約55,000人がそのような治療を受けることを示しています。この数字は2020年の約53,000人の患者から増加しており、増加傾向を強調しています。体外受精の利用に貢献し、その後排卵誘発剤市場の成長に貢献しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の排卵誘発剤市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• ホルモン
• 治療薬
• 世界の排卵誘発剤市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• その他
• 世界の排卵誘発剤市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
• 病院
• 在宅ケア
• 専門クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の排卵誘発剤市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の排卵誘発剤市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 排卵誘発剤市場の競合情勢
• 排卵誘発剤市場の企業プロファイル
  • Pfizer Inc.
  • Johnson And Johnson Pvt Ltd.
  • Merck And Co. Inc.
  • Abbvie Inc.
  • Novartis AG

第31章 その他の大手および革新的な企業

• Bayer AG
• Sanofi SA
• Abbott Laboratories
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Janssen Pharmaceutical Inc.
• Mylan NV
• Astellas Pharma Inc.
• Sun Pharmaceuticals Industries Ltd.
• Aurobindo Pharma Limited
• Dr Reddy's Laboratories Ltd.
• Intas Pharmaceuticals Limited
• Endo International Inc.
• Ferring Pharmaceuticals Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Ovulation-inducing drugs are medications used to stimulate the ovaries and facilitate the release of mature eggs (ovulation) in women facing challenges with their menstrual cycles or struggling with infertility. These drugs exert their effects on the hormonal balance in the body, specifically targeting the hormones involved in the ovulation process.

The primary types of ovulation-inducing drugs include hormones and therapeutic drugs. Hormone drugs are medications designed to modify or mimic the effects of naturally occurring hormones in the body. They can be administered through oral, topical, and other routes and are utilized by various end-users, including hospitals, homecare, specialty clinics, and others.

The ovulation-inducing drug market research report is one of a series of new reports from The Business Research Company that provides ovulation-inducing drug market statistics, including ovulation-inducing drug industry global market size, regional shares, competitors with a ovulation-inducing drug market share, detailed ovulation-inducing drug market segments, market trends and opportunities, and any further data you may need to thrive in the ovulation-inducing drug industry. This ovulation-inducing drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovulation inducing drugs market size has grown strongly in recent years. It will grow from $4.11 billion in 2023 to $4.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth observed during the historical period can be attributed to the development of clomiphene citrate, the introduction of letrozole, regulatory approvals, standardization, and the emergence of ovulation predictor kits.

The ovulation inducing drugs market size is expected to see strong growth in the next few years. It will grow to $5.7 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to changing lifestyles and delayed childbearing, the integration of digital health, expanding market reach, increasing infertility rates, and the adoption of customized treatment regimens. Major trends expected during the forecast period include personalized treatment approaches, advancements in reproductive endocrinology, non-invasive fertility monitoring, a rising demand for assisted reproductive technologies, and the development of novel drug formulations.

The anticipated increase in the prevalence of women's infertility is poised to drive the expansion of the ovulation-inducing drug market. Women's infertility, characterized by the inability to conceive or carry a pregnancy to full term despite regular unprotected sexual intercourse, affects a significant percentage of women aged 15 to 44. Ovulation-inducing drugs, designed to address issues of irregular or absent ovulation, target hormonal pathways involved in the ovulation process, stimulating the release of mature eggs from the ovaries. For example, data from the Centers for Disease Control and Prevention reveals that approximately 10% of women in the US, totaling 6.1 million, face difficulties becoming pregnant. Additionally, CCRM Management Company LLC reports that infertility impacts 1 in 4 couples globally, with a yearly increase of 5% to 10%. Consequently, the growing prevalence of women's infertility acts as a key driver for the ovulation-inducing drug market.

The surge in patients opting for in vitro fertilization (IVF) is anticipated to fuel the ovulation-inducing drugs market's growth. IVF, a series of complex procedures aiding individuals and couples with fertility challenges, involves the use of ovulation-inducing drugs to stimulate ovaries and enhance egg production for retrieval. This approach is integral to optimizing the success rate of IVF procedures. Notably, a report from the Human Fertilization and Embryology Authority indicates an increase in IVF and donor insemination treatments in the UK, with around 55,000 people receiving such treatments in 2023. This figure represents a rise from approximately 53,000 patients in 2020, underscoring the upward trend in IVF utilization and subsequently contributing to the growth of the ovulation-inducing drugs market.

The development of alternative treatments is expected to pose a challenge to the ovulation-inducing drugs market. Alternatives such as Tamoxifen, complementary and alternative medicine (CAM), fertility surgery (FS), and IVF provide women with additional options for addressing ovulation disorders and enhancing the likelihood of pregnancy. The emergence of these alternative treatments introduces heightened competition to the ovulation-inducing drugs market. For example, the introduction of injected treatments such as Gonadotropins, specifically human menopausal gonadotropin (hMG) and follicle-stimulating hormone (FSH), has provided alternatives that stimulate ovarian activity. This variety of options in the market poses a restraint on the growth of ovulation-inducing drugs.

Major companies in the ovulation-inducing drugs market are proactively developing innovative drugs such as Cetrorelix acetate to secure approvals for treating women undergoing controlled ovarian stimulation. Cetrorelix acetate for injection, a gonadotropin-releasing hormone (GnRH) antagonist, has gained FDA approval, demonstrating its efficacy in preventing premature ovulation in women undergoing in vitro fertilization (IVF). In August 2022, Akorn Operating Company LLC received FDA approval for a generic version of cetrorelix acetate for injection, marking a significant advancement in fertility treatment. This development is aligned with the ongoing efforts of pharmaceutical companies, such as Akorn, to address infertility through innovative drugs.

In January 2021, Koninklijke Philips N.V, a health technology company, collaborated with Merck & Co. Inc., a pharmaceutical company specializing in ovulation-inducing drugs. This partnership aims to enhance the success rates of fertility treatments and ease the path to parenthood for couples grappling with infertility challenges. Overall, these strategic endeavors demonstrate the commitment of major companies to innovate and drive advancements in the ovulation-inducing drugs market.

Major companies operating in the ovulation inducing drugs market report are Pfizer Inc., Johnson And Johnson Pvt Ltd., Merck And Co. Inc., Abbvie Inc., Novartis AG, Bayer AG, Sanofi SA, Abbott Laboratories, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceutical Inc., Mylan N.V, Astellas Pharma Inc., Sun Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Dr Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Endo International Inc., Ferring Pharmaceuticals Inc., Lupin Limited, LIVZON Pharmaceutical Group Inc., Torrent Pharmaceuticals Ltd., Gedeon Richter plc, Glenmark Pharmaceuticals Ltd., Fresenius Kabi AG, Zydus Pharmaceuticals (USA) Inc., Serum Institute of India Ltd., EMD Serono Inc., Cipla Inc.

North America was the largest region in the ovulation-inducing drugs market in 2023. The regions covered in the ovulation inducing drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ovulation inducing drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ovulation-inducing drugs market consists of sales of clomiphene citrate (Clomid), letrozole (Femara), gonadotropins, human chorionic gonadotropin (hCG), bromocriptine (Cycloset, Parlodel). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovulation Inducing Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovulation inducing drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovulation inducing drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovulation inducing drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Class: Hormones; Therapeutics Drugs
• 2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 3) By End-User: Hospital; Homecare; Specialty Clinics; Other End-Users
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson Pvt Ltd.; Merck And Co. Inc.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovulation Inducing Drugs Market Characteristics

3. Ovulation Inducing Drugs Market Trends And Strategies

4. Ovulation Inducing Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Ovulation Inducing Drugs Market Size and Growth

• 5.1. Global Ovulation Inducing Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Ovulation Inducing Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Ovulation Inducing Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Ovulation Inducing Drugs Market Segmentation

• 6.1. Global Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hormones
• Therapeutics Drugs
• 6.2. Global Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.3. Global Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users

7. Ovulation Inducing Drugs Market Regional And Country Analysis

• 7.1. Global Ovulation Inducing Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Ovulation Inducing Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Ovulation Inducing Drugs Market

• 8.1. Asia-Pacific Ovulation Inducing Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Ovulation Inducing Drugs Market

• 9.1. China Ovulation Inducing Drugs Market Overview
• 9.2. China Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Ovulation Inducing Drugs Market

• 10.1. India Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Ovulation Inducing Drugs Market

• 11.1. Japan Ovulation Inducing Drugs Market Overview
• 11.2. Japan Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Ovulation Inducing Drugs Market

• 12.1. Australia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Ovulation Inducing Drugs Market

• 13.1. Indonesia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Ovulation Inducing Drugs Market

• 14.1. South Korea Ovulation Inducing Drugs Market Overview
• 14.2. South Korea Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Ovulation Inducing Drugs Market

• 15.1. Western Europe Ovulation Inducing Drugs Market Overview
• 15.2. Western Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Ovulation Inducing Drugs Market

• 16.1. UK Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Ovulation Inducing Drugs Market

• 17.1. Germany Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Ovulation Inducing Drugs Market

• 18.5. France Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.6. France Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.7. France Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Ovulation Inducing Drugs Market

• 19.9. Italy Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.10. Italy Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.11. Italy Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Ovulation Inducing Drugs Market

• 20.13. Spain Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.14. Spain Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Ovulation Inducing Drugs Market

• 21.1. Eastern Europe Ovulation Inducing Drugs Market Overview
• 21.2. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Ovulation Inducing Drugs Market

• 22.1. Russia Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Ovulation Inducing Drugs Market

• 23.1. North America Ovulation Inducing Drugs Market Overview
• 23.2. North America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Ovulation Inducing Drugs Market

• 24.1. USA Ovulation Inducing Drugs Market Overview
• 24.2. USA Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Ovulation Inducing Drugs Market

• 25.1. Canada Ovulation Inducing Drugs Market Overview
• 25.2. Canada Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Ovulation Inducing Drugs Market

• 26.1. South America Ovulation Inducing Drugs Market Overview
• 26.2. South America Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Ovulation Inducing Drugs Market

• 27.1. Brazil Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Ovulation Inducing Drugs Market

• 28.1. Middle East Ovulation Inducing Drugs Market Overview
• 28.2. Middle East Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Ovulation Inducing Drugs Market

• 29.1. Africa Ovulation Inducing Drugs Market Overview
• 29.2. Africa Ovulation Inducing Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Ovulation Inducing Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Ovulation Inducing Drugs Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Ovulation Inducing Drugs Market Competitive Landscape And Company Profiles

• 30.1. Ovulation Inducing Drugs Market Competitive Landscape
• 30.2. Ovulation Inducing Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson And Johnson Pvt Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Merck And Co. Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Abbvie Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Novartis AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Ovulation Inducing Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi SA
• 31.3. Abbott Laboratories
• 31.4. Gilead Sciences Inc.
• 31.5. Amgen Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Janssen Pharmaceutical Inc.
• 31.8. Mylan N.V
• 31.9. Astellas Pharma Inc.
• 31.10. Sun Pharmaceuticals Industries Ltd.
• 31.11. Aurobindo Pharma Limited
• 31.12. Dr Reddy's Laboratories Ltd.
• 31.13. Intas Pharmaceuticals Limited
• 31.14. Endo International Inc.
• 31.15. Ferring Pharmaceuticals Inc.

32. Global Ovulation Inducing Drugs Market Competitive Benchmarking

33. Global Ovulation Inducing Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ovulation Inducing Drugs Market

35. Ovulation Inducing Drugs Market Future Outlook and Potential Analysis

• 35.1 Ovulation Inducing Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Ovulation Inducing Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Ovulation Inducing Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer